Status of Spinal Muscular Atrophy Newborn Screening in Europe
National Program Active
SMA approved for NBS panel, pending implementation
Application for national program submitted
No information available currently
This is an interactive map, click on a country to learn more about the status of SMA newborn screening.
– As of 1 October 2021, both Germany and Norway screen all newborns in that country for SMA.
– As of 1 January 2022, Belgium screens all newborns for SMA, previously it had just been the Wallonia region.
– As of 1 June 2022, the Netherlands screens all newborns for SMA.
– As of Spring 2021, Spinal Muscular Atrophy (SMA) is approved as part of the national newborn screening programme and awaiting implementation in Slovenia.
– As of July 2022, there are newborn screening pilots for SMA ongoing in Spain (Sevilla, Malaga) and the United Kingdom (Oxford) and France.
– Pilots have been applied for in Ireland and Portugal and are expected to start soon.
– Germany, Italy, and Belgium concluded their pilot studies and SMA newborn screening continues in those countries.
– Italy will continue to screen for SMA with state-sponsored screening in the regions of Lazio and Tuscany at the regional level and is expanding to more regions in 2022, though not yet nationally approved.
– SMA NBS in Poland was approved in March 2021 and is now undergoing staggered implementation, province by province, starting in April 2021. The last province is planned to enter the programme in November 2022. The implementation is currently ahead of schedule and as of now, it covers 12 out of 16 provinces which account for approx. 70% of live births in Poland.
– Nationwide SMA newborn screening started in Turkey on May 9, 2022 Source
– As of August 2022, the United States has 47/50 states screening at birth for SMA. Source
– As of August 2022, the application for SMA newborn screening was confirmed by the special Committee of the Ministry of Health and the reimbursement was approved by the Council of Compulsory Health Insurance. Therefore, the chair of the Lithuanian Association of Child Neurology expects to start testing for SMA as part of the national newborn screening program in 2023.
A pilot is a small, normally regional, study to test newborn screening research protocols, data collection instruments, sample strategies, and other research techniques in preparation for a larger study or implementation of newborn screening for SMA nationwide.